MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.95
-0.48
-5.09%
After Hours: 8.95 0 0.00% 17:01 04/03 EDT
OPEN
9.36
PREV CLOSE
9.43
HIGH
9.55
LOW
8.82
VOLUME
829.86K
TURNOVER
--
52 WEEK HIGH
16.22
52 WEEK LOW
4.950
MARKET CAP
979.14M
P/E (TTM)
-4.6306
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TGTX stock price target is 21.50 with a high estimate of 25.00 and a low estimate of 18.00.

EPS

TGTX News

More
  • TG Therapeutics (TGTX) Upgraded to Buy: What Does It Mean for the Stock?
  • Zacks · 03/25 17:00
  • Edited Transcript of TGTX earnings conference call or presentation 3-Mar-20 1:00pm GMT
  • Thomson Reuters StreetEvents · 03/25 10:19
  • Did You Manage To Avoid TG Therapeutics's (NASDAQ:TGTX) Painful 52% Share Price Drop?
  • Simply Wall St. · 03/22 15:39
  • TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
  • GlobeNewswire · 03/09 13:00

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About TGTX

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.
More

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.